- Home
- NUVL vs GDS Comparison
NUVL vs GDS Comparison
Compare NUVL & GDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- GDS
- Stock Information
- Founded
- NUVL 2017
- GDS 2001
- Country
- NUVL United States
- GDS China
- Employees
- NUVL N/A
- GDS N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- GDS Computer Software: Programming Data Processing
- Sector
- NUVL Health Care
- GDS Technology
- Exchange
- NUVL Nasdaq
- GDS Nasdaq
- Market Cap
- NUVL 6.5B
- GDS 7.4B
- IPO Year
- NUVL 2021
- GDS 2016
- Fundamental
- Price
- NUVL $98.17
- GDS $35.53
- Analyst Decision
- NUVL Strong Buy
- GDS Strong Buy
- Analyst Count
- NUVL 11
- GDS 7
- Target Price
- NUVL $121.45
- GDS $47.51
- AVG Volume (30 Days)
- NUVL 527.5K
- GDS 2.1M
- Earning Date
- NUVL 10-30-2025
- GDS 11-18-2025
- Dividend Yield
- NUVL N/A
- GDS N/A
- EPS Growth
- NUVL N/A
- GDS N/A
- EPS
- NUVL N/A
- GDS 3.46
- Revenue
- NUVL N/A
- GDS $1,526,241,101.00
- Revenue This Year
- NUVL N/A
- GDS $13.40
- Revenue Next Year
- NUVL N/A
- GDS $14.16
- P/E Ratio
- NUVL N/A
- GDS $180.95
- Revenue Growth
- NUVL N/A
- GDS 10.29
- 52 Week Low
- NUVL $55.54
- GDS $16.93
- 52 Week High
- NUVL $104.90
- GDS $52.50
- Technical
- Relative Strength Index (RSI)
- NUVL 60.96
- GDS 48.88
- Support Level
- NUVL $90.00
- GDS $35.25
- Resistance Level
- NUVL $99.94
- GDS $38.35
- Average True Range (ATR)
- NUVL 5.06
- GDS 1.18
- MACD
- NUVL 0.69
- GDS 0.19
- Stochastic Oscillator
- NUVL 66.81
- GDS 54.81
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About GDS GDS Holdings Limited ADS
GDS Holdings started as an IT service provider in 2001 then moved to the data center business with its first self-developed data center opening in 2010. The company now develops and operates data centers in China and also builds, operates and transfers data centers for other clients. It offers colocation and managed services and mainly targets hyperscale cloud service customers who take large areas of its data centers or even whole data centers under long-term contracts. Its data centers are located predominantly in and around the Tier 1 cities in China and it has also started an expanding into Southeast Asia via the now 38% owned DayOne. GDS listed on the Nasdaq in 2016 and completed a secondary listing in Hong Kong in 2020.